Back

AAV-delivered CRISPR-Cas9 elicits persistent retinal immune responses compared with transient responses to RNP

Pulman, J.; REN, D.; Visticot, L.; Malki, H.; Yao, Y.; De Cian, A.; Ail, D.; Concordet, J.-P.; Dalkara, D.; Fisson, S.

2025-12-14 bioengineering
10.64898/2025.12.11.693665 bioRxiv
Show abstract

CRISPR-Cas9 is a powerful gene-editing tool with great potential for treating genetic diseases, including inherited retinal disorders. However, its bacterial origin can induce immune responses that may eliminate transduced cells, threatening editing efficiency. A deeper understanding of CRISPR-Cas9 immunogenicity is therefore needed. Previous studies have shown that systemic delivery via Cas9 induces an immune response, but the detailed inflammation and the impact of the vector remain unclear, especially in immune-privileged organs like the eye. In this study, we found that Cas9 delivered to the retina using adeno-associated virus (AAV) induced persistent inflammation, whereas delivery as naked ribonucleoprotein (RNP) complexes resulted in acute inflammation that faded three weeks post-injection. Inflammation was more severe in the rd10 mouse model of inherited retinal degeneration, which exhibits basal inflammation. These findings provide new insights into vector-dependent immune responses to Cas9 in the eye and highlight potential risks associated with its clinical application. TEASERUnderstanding immune reactions to CRISPR-Cas9 and linking these to their delivery methodology increases their safety.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
○ 71 papers in training set
Top 0.1%
28.5%
2
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.1%
14.8%
3
Molecular Therapy Methods & Clinical Development
○ 13 papers in training set
Top 0.1%
6.5%
4
Scientific Reports
○ 3102 papers in training set
Top 30%
4.1%
50% of probability mass above
5
Experimental Eye Research
○ 30 papers in training set
Top 0.2%
3.4%
6
Molecular Therapy Nucleic Acids
○ 32 papers in training set
Top 0.2%
2.8%
7
Translational Vision Science & Technology
● 35 papers in training set
Top 0.3%
2.1%
8
Molecular Therapy - Nucleic Acids
○ 24 papers in training set
Top 0.1%
2.1%
9
Stem Cell Research & Therapy
○ 30 papers in training set
Top 0.3%
1.9%
10
Investigative Ophthalmology & Visual Science
● 22 papers in training set
Top 0.2%
1.8%
11
Cell Reports Medicine
○ 140 papers in training set
Top 3%
1.7%
12
Investigative Opthalmology & Visual Science
● 37 papers in training set
Top 0.4%
1.7%
13
PLOS ONE
● 4510 papers in training set
Top 58%
1.4%
14
Frontiers in Bioengineering and Biotechnology
○ 88 papers in training set
Top 2%
1.0%
15
eLife
● 5422 papers in training set
Top 52%
0.9%
16
Nature Communications
○ 4913 papers in training set
Top 59%
0.9%
17
Bioengineering & Translational Medicine
○ 21 papers in training set
Top 0.8%
0.8%
18
The CRISPR Journal
○ 33 papers in training set
Top 0.3%
0.8%
19
Neurobiology of Disease
○ 134 papers in training set
Top 4%
0.8%
20
Communications Medicine
○ 85 papers in training set
Top 1%
0.7%
21
Frontiers in Cellular Neuroscience
○ 79 papers in training set
Top 1%
0.7%
22
iScience
○ 1063 papers in training set
Top 33%
0.7%
23
Proceedings of the National Academy of Sciences
● 2130 papers in training set
Top 46%
0.7%
24
Cell Proliferation
○ 12 papers in training set
Top 0.5%
0.7%
25
Journal of Investigative Dermatology
○ 42 papers in training set
Top 0.6%
0.7%
26
Science Bulletin
○ 22 papers in training set
Top 1%
0.7%
27
Clinical and Translational Science
○ 21 papers in training set
Top 1%
0.7%
28
Diabetes
● 53 papers in training set
Top 0.8%
0.5%
29
Molecular Pharmaceutics
● 16 papers in training set
Top 0.7%
0.5%
30
International Journal of Molecular Sciences
○ 453 papers in training set
Top 19%
0.5%